Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (5y) (2017 - 2026)
Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.15% |
| Dec 31, 2025 | 16.66% |
| Sep 30, 2025 | 0.33% |
| Jun 30, 2025 | -21.09% |
| Mar 31, 2025 | -20.39% |
| Dec 31, 2024 | 31.89% |
| Sep 30, 2024 | 15.26% |
| Jun 30, 2024 | -18.62% |
| Mar 31, 2024 | -5.70% |
| Dec 31, 2023 | -44.70% |
| Sep 30, 2023 | -19.70% |
| Jun 30, 2023 | 23.73% |
| Mar 31, 2023 | 96.73% |
| Dec 31, 2022 | -22.38% |
| Sep 30, 2022 | -18.48% |
| Jun 30, 2022 | -38.16% |
| Mar 31, 2022 | -110.45% |
| Dec 31, 2021 | 59.61% |
| Sep 30, 2021 | 53.08% |
| Jun 30, 2021 | -18.10% |